Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

2,817 total articles

Abbott: Upgrade to Buy Ahead of Q1 — A Clearer Path to Rebound

Abbott: Upgrade to Buy Ahead of Q1 — A Clearer Path to Rebound

We upgrade Abbott Laboratories (ABT) to Buy ahead of Q1 results. At $103.52, the shares trade below near-term averages with a PE ~27.6, a healthy dividend yield (~2.3%), and strong free cash flow ($7.4B). Recent weakness centers on diagnostics and nutrition, but medical devices growth, a manageable balance sheet (debt/equity 0.25), and the $21B Exa…

Lumentum: AI Optics Rally Has Room to Run — A Tactical Long

Lumentum: AI Optics Rally Has Room to Run — A Tactical Long

Lumentum is squarely in the middle of an optical upgrade cycle for AI data centers. With an S&P 500 addition, a $2 billion strategic allocation from NVIDIA, and accelerating revenue and earnings prints, LITE has momentum. Valuation is rich, so the trade is a tactical long with a defined stop and multi-horizon targets.

Buy on Value: Laureate's Recovery Looks Real and Underpriced

Buy on Value: Laureate's Recovery Looks Real and Underpriced

Laureate Education ($LAUR) looks like a value compounder trading at sensible multiples after a strong enrollment-driven recovery and a renewed $100M repurchase program. With a market cap near $5.05B, free cash flow of $263.1M and an EV/EBITDA of 9.8, we set a long-term trade targeting $45 while protecting capital with a $30 stop.

Nvidia's $2B Bet Rewrites Marvell's AI Playbook

Nvidia's $2B Bet Rewrites Marvell's AI Playbook

Nvidia's announced $2 billion investment and strategic partnership with Marvell transforms Marvell from a fast-growing networking and storage ASIC vendor into a core partner for hyperscale AI infrastructure. With data-center revenue up 21% year-over-year and management guiding revenue to roughly $11 billion, Marvell has the growth profile and cash …

Abivax: Obefazimod’s Scarcity Is the Optionality — Maintain Buy

Abivax: Obefazimod’s Scarcity Is the Optionality — Maintain Buy

Abivax (ABVX) remains a compelling long idea. Obefazimod's differentiated data package, emerging anti-fibrotic signal and concentrated asset base create strategic scarcity that magnifies upside from a successful Phase 3 maintenance readout in Q2 2026 or a takeover bid. We maintain Buy: enter at $117.65, target $150.00, stop $95.00. Trade horizon: l…

Netflix: Upgrade to Buy — An Earnings-Driven Long With Conviction

Netflix: Upgrade to Buy — An Earnings-Driven Long With Conviction

We upgrade Netflix to Buy and propose an aggressive long ahead of the next earnings print. Netflix combines strong operating margins, meaningful free cash flow ($9.46B trailing), and a growing ad business that management expects to double in 2026. At $95.32 the risk/reward favors a long exposure into earnings and the post-earnings reaction, but thi…

Meta's Underrated AI Revenue Pipeline: A Re-rate Play at $582

Meta's Underrated AI Revenue Pipeline: A Re-rate Play at $582

Meta is trading at roughly $1.47T with $46.1B in free cash flow and a PE of ~24. Management's AI product stack — from ad targeting to developer APIs and AR experiences — has near-term revenue vectors that the market is underpricing. I outline a long trade with entry, stop and target plus catalysts and risks.

Microsoft at a Discount: High-Quality Cash Flow Meets AI Upside

Microsoft at a Discount: High-Quality Cash Flow Meets AI Upside

Microsoft's share price has retreated from 52-week highs while fundamentals remain robust: $2.76T market cap, $77B in free cash flow and a 30% return on equity. For value-minded investors who believe AI adoption sustains enterprise spending, MSFT is an actionable long with a clear entry, stop and upside target over the next 180 trading days.

Constellation Brands: A Tactical Long on Cheap Consumer Alcohol Exposure

Constellation Brands: A Tactical Long on Cheap Consumer Alcohol Exposure

Constellation Brands (STZ) looks like an actionable long after a difficult 2025 and early-2026 pullback. The business still generates strong free cash flow ($1.76B), carries a $26B market cap and a 2.95% yield, and is trading near $149. This trade targets a recovery back toward Street estimates and prior analyst targets while protecting capital wit…

Marvell Gets a Shot of Jet Fuel from Nvidia - Tactical Long Idea

Marvell Gets a Shot of Jet Fuel from Nvidia - Tactical Long Idea

Marvell just secured a transformational strategic partnership with Nvidia that pairs Marvell's networking, custom processors and silicon-photonics strengths with Nvidia's AI compute scale. With data-center revenue growing 21% year-over-year and management guiding to ~40% in fiscal 2027, Marvell's growth trajectory and reasonable cash generation arg…

J.Jill Looked Cheap at the Bottom: A Tactical Long After the Melt-Down

J.Jill Looked Cheap at the Bottom: A Tactical Long After the Melt-Down

J.Jill (JILL) has been punished to near-term lows after weak top-line trends and margin pressure. At roughly $11.56, the shares trade below $12 with a market cap near $175M, earnings of about $2.26 per share and compelling cash flow metrics. The combination of a low P/E (~5-6), EV/EBITDA ~2.36, a dividend yield near 2.8%, and a heavily oversold tec…